Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel

Francisca Mutapi; Nadine Rujeni; Claire Bourke; Kate Mitchell; Laura Appleby; Norman Nausch; Nicholas Midzi; Takafira Mduluza

doi:10.1371/journal.pntd.0001143

Loading metrics

Open Access

Peer-reviewed

Research Article

Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel

Francisca Mutapi ,

* E-mail: f.mutapi@ed.ac.uk

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Nadine Rujeni,

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Claire Bourke,

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Kate Mitchell,

Current address: London School of Hygiene and Tropical Medicine, London, United Kingdom

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Laura Appleby,

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Norman Nausch,

Affiliation Ashworth Laboratories, Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom
⨯
Nicholas Midzi,

Affiliation National Institute of Health Research, Causeway, Harare, Zimbabwe
⨯
Takafira Mduluza

Current address: Botswana Harvard AIDS Institute, Gaborone, Botswana

Affiliation Department of Biochemistry, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe
⨯

Schistosoma haematobium Treatment in 1–5 Year Old Children: Safety and Efficacy of the Antihelminthic Drug Praziquantel

Francisca Mutapi,
Nadine Rujeni,
Claire Bourke,
Kate Mitchell,
Laura Appleby,
Norman Nausch,
Nicholas Midzi,
Takafira Mduluza

Published: May 17, 2011
https://doi.org/10.1371/journal.pntd.0001143

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Schistosoma
Is the Subject Area "Schistosoma" applicable to this article?

Thanks for your feedback.
Age groups
Is the Subject Area "Age groups" applicable to this article?

Thanks for your feedback.
Schistosoma haematobium
Is the Subject Area "Schistosoma haematobium" applicable to this article?

Thanks for your feedback.
Urine
Is the Subject Area "Urine" applicable to this article?

Thanks for your feedback.
Eggs
Is the Subject Area "Eggs" applicable to this article?

Thanks for your feedback.
Adverse reactions
Is the Subject Area "Adverse reactions" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.